AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Palisade Bio Plunges 11.48% Despite Positive Trial Results
Generated by AI AgentAinvest Pre-Market Radar
Thursday, Jul 24, 2025 5:51 am ET1min read
Aime SummaryOn July 24, 2025, Palisade Bio's stock experienced a significant drop of 11.48% in pre-market trading.
Palisade Bio recently reported positive Phase 1a results for PALI-2108, a first-in-class terminal ileum and colon-targeted PDE4 B/D inhibitor designed for fibrostenotic Crohn's disease. This development is a significant milestone for the company, as it demonstrates the potential efficacy of their novel therapeutic approach.
The company also announced an agreement with several accredited investors to exercise existing warrants, raising approximately $3.9 million. This capital infusion is expected to support the company's working capital and general corporate purposes, providing a financial boost to continue its research and development efforts.
Additionally,
participated in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand Conference, showcasing its commitment to engaging with the investment community and highlighting its innovative pipeline.
Ainvest Pre-Market Radar
Get the scoop on pre-market movers and shakers in the US stock market.
Latest Articles
Getty Images (NYSE:GETY) surges 5.51% on renewed investor confidence
Jan.02 2026
Olaplex Holdings (NASDAQ: OLPX) shares plunged 7.59% on mixed analyst outlooks and shifting institutional positioning.
Jan.02 2026
The Real Brokerage shares surge 7.04% on Jan. 2 2026 driven by regulatory tailwinds and restructuring optimism
Jan.02 2026
Vanda Pharmaceuticals shares surged 25.46% on partnership and FDA Breakthrough Therapy Designation.
Jan.02 2026
Vanda Pharmaceuticals shares surge 25.46% on partnership and FDA breakthrough designation
Jan.02 2026
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet